Form4insider filings, from the source

SEC Form 4 · accession 0001209191-18-010105

VERTEX PHARMACEUTICALS INC / MA · VRTX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
Jeffrey M Leiden
Officer — CEO & President · Director
Period of report
Feb 12, 2018
Accepted (ET)
Feb 14, 2018 · 6:06 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common StockF2,F3Feb 12, 2018S6,100$149.22D208,463D
Common StockF3,F4Feb 12, 2018S4,305$150.44D204,158D
Common StockF3,F5Feb 12, 2018S10,100$151.23D194,058D
Common StockF3,F6Feb 12, 2018S1,200$152.40D192,858D
Common StockF3,F7Feb 12, 2018S2,000$153.29D190,858D
Common StockF3,F8Feb 12, 2018S200$153.89D190,658D
Common Stockholding———440I401(k)

Table II — derivative securities

No Table II lines on this filing.

Explanation of responses